Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/20/2017 09/21/2017 09/22/2017 09/25/2017 09/26/2017 Date
135(c) 135(c) 132(c) 133.5(c) 130.5 Last
6 863 77 11 203 30 281 4 374 Volume
+0.37% 0.00% -2.22% +1.14% -2.25% Change
More quotes
Financials ($)
Sales 2017 1,63 M
EBIT 2017 -120 M
Net income 2017 -97,2 M
Finance 2017 55,7 M
Yield 2017 -
Sales 2018 2,85 M
EBIT 2018 -130 M
Net income 2018 -101 M
Finance 2018 53,1 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 229x
EV / Sales2018 131x
Capitalization 428 M
More Financials
Company
PureTech Health Plc is a cross-disciplinary biopharmacy company, which engages in the development of treatment programs for obesity, cognitive disorders, baldness, depression, allergy, and autoimmune.It operates through the following segments: Growth Stage Businesses; Project Phase Businesses; and... 
More about the company
Surperformance© ratings of Puretech Health PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on PURETECH HEALTH PLC
09/25 GELESIS : 100 Achieves Significant Weight Loss with Excellent Safety Profile in ..
09/25 PURETECH HEALTH : Gelesis Reports Significant Weight Loss with Excellent Safety ..
09/20 PURETECH HEALTH : Notes US Patent Issuance Broadly Covering Methods of Assessing..
09/20 PURETECH HEALTH : Notes U.S. Patent Issuance Broadly Covering Methods of Assessi..
09/07 PURETECH HEALTH : Exclusively Licenses Glyph Technology from Monash University t..
08/29 PURETECH HEALTH : Exclusively Licenses Glyph Technology from Monash University t..
08/25PURETECH HEALTH PLC : half-yearly earnings release
08/15 PURETECH HEALTH : Notice of Half-Yearly Results
07/13 PURETECH HEALTH : Presents Data Supporting Treatment Approach for Interstitial C..
07/12 PURETECH HEALTH : Gelesis Announces Last Patient Visit in the Pivotal Gelesis100..
More news
Sector news : Biotechnology & Medical Research - NEC
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/25Puretech Health PLC's buy rating reiterated at N+1 Singer.  
09/25Puretech Health PLC's buy rating reiterated at Numis Securities Ltd. GBX 207 .. 
09/25Puretech Health PLC's buy rating reiterated at Liberum Capital. GBX 248 PT.  
09/25Puretech Health PLC's buy rating reiterated at Peel Hunt. GBX 259 PT.  
09/20PureTech Health Notes U.S. Patent Issuance Broadly Covering Methods of Assess.. 
More tweets
Qtime:6
Chart PURETECH HEALTH PLC
Duration : Period :
Puretech Health PLC Technical Analysis Chart | PRTC | GB00BY2Z0H74 | 4-Traders
Technical analysis trends PURETECH HEALTH PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 3,13 $
Spread / Average Target 74%
EPS Revisions
Managers
NameTitle
Daphne Zohar Chief Executive Officer & Executive Director
Bharatt M. Chowrira President, Chief Business & Strategy Officer
Joichi Ito Non-Executive Chairman
Stephen Muniz Chief Operations Officer, Secretary & Director
Eric Elenko Chief-Research & Strategy
Sector and Competitors
1st jan.Capitalization (M$)
PURETECH HEALTH PLC11.98%428
INCYTE CORPORATION14.74%23 106
QUINTILES IMS HOLDINGS INC23.89%20 424
LONZA GROUP56.52%19 640
CELLTRION, INC.--.--%15 871
ALNYLAM PHARMACEUTICALS, INC.203.95%10 736